Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-550-7500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$251.45 million
Profitability
Miscellaneous
Employees116
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) released its earnings results on Tuesday, July, 30th. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.38 by $0.30. The biotechnology company had revenue of $24.99 million for the quarter, compared to the consensus estimate of $21.01 million. Ligand Pharmaceuticals had a net margin of 389.58% and a return on equity of 11.24%. Ligand Pharmaceuticals's quarterly revenue was down 72.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.59 EPS. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $3.20-3.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.26. The company issued revenue guidance of $118-118 million, compared to the consensus revenue estimate of $119.98 million.
What price target have analysts set for LGND?
4 brokers have issued twelve-month price targets for Ligand Pharmaceuticals' stock. Their predictions range from $132.00 to $214.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $166.50 in the next twelve months. This suggests a possible upside of 57.2% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.
What is the consensus analysts' recommendation for Ligand Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ligand reported encouraging second-quarter results with earnings and sales beating estimates. The company’s Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Ligand is acquiring other technology platforms like OmniAb platform from OMT acquisition to reduce dependence on Captisol formulation. OmniAb is likely to drive future revenues. However, Shares of Ligand have underperformed the industry so far this year. Moreover, Ligand derives a substantial portion of its revenues from royalties associated with the sales of Kyprolis. Any setback to Kyprolis will have an unfavorable impact on the top line. Moreover, increase in inactive licensing deals related to Ligand’s technology platform raises concerns." (8/8/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $214 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (5/3/2019)
Has Ligand Pharmaceuticals been receiving favorable news coverage?
Media coverage about LGND stock has trended very negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ligand Pharmaceuticals earned a daily sentiment score of -3.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Ligand Pharmaceuticals.
Are investors shorting Ligand Pharmaceuticals?
Ligand Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 7,320,000 shares, an increase of 13.3% from the August 30th total of 6,460,000 shares. Based on an average daily trading volume, of 434,700 shares, the days-to-cover ratio is currently 16.8 days. Currently, 39.7% of the shares of the stock are sold short. View Ligand Pharmaceuticals' Current Options Chain.
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), The Medicines (MDCO) and Ascendis Pharma A/S (ASND).
What other stocks do shareholders of Ligand Pharmaceuticals own?
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 49)
- Mr. Matthew W. Foehr, Pres & COO (Age 46)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)
- Mr. Todd Pettingill, Director of Corp. Devel.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Stephens Investment Management Group LLC (2.69%), Summit Creek Advisors LLC (0.38%), CIBC Private Wealth Group LLC (0.36%), Stephens Inc. AR (0.14%), Pacer Advisors Inc. (0.04%) and Coe Capital Management LLC (0.03%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba, Sunil Patel and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which major investors are selling Ligand Pharmaceuticals stock?
Which major investors are buying Ligand Pharmaceuticals stock?
LGND stock was purchased by a variety of institutional investors in the last quarter, including Stephens Investment Management Group LLC, State of Alaska Department of Revenue, Summit Creek Advisors LLC, Nisa Investment Advisors LLC and Coe Capital Management LLC. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins and Sunil Patel. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $105.93.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $2.01 billion and generates $251.45 million in revenue each year. The biotechnology company earns $143.32 million in net income (profit) each year or $6.28 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.View Additional Information About Ligand Pharmaceuticals.
What is Ligand Pharmaceuticals' official website?
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
